These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [NY-ESO-1 and cancer immunotherapy].
    Author: Peng JR, Leng XS.
    Journal: Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604.
    Abstract:
    NY-ESO-1 is an important member of cancer-testis antigen family and is widely distributed among many cancer types. As a tumor-specific antigen with the strongest immunogenicity so far identified, it can induce spontaneous antibody and T-cell responses in patients with NY-ESO-1-positive tumors. Therefore, it has been a good vaccine candidate in the immunotherapy against many malignancies. This article reviews the recent research advances in NY-ESO-1 and its relevant vaccines.
    [Abstract] [Full Text] [Related] [New Search]